These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
377 related articles for article (PubMed ID: 19845257)
1. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina. Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257 [TBL] [Abstract][Full Text] [Related]
2. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Zatelli MC; Torta M; Leon A; Ambrosio MR; Gion M; Tomassetti P; De Braud F; Delle Fave G; Dogliotti L; degli Uberti EC; Endocr Relat Cancer; 2007 Jun; 14(2):473-82. PubMed ID: 17639060 [TBL] [Abstract][Full Text] [Related]
3. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors]. Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832 [TBL] [Abstract][Full Text] [Related]
4. Chromogranin A: is it a useful marker of neuroendocrine tumors? Campana D; Nori F; Piscitelli L; Morselli-Labate AM; Pezzilli R; Corinaldesi R; Tomassetti P J Clin Oncol; 2007 May; 25(15):1967-73. PubMed ID: 17513802 [TBL] [Abstract][Full Text] [Related]
5. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? Walter T; Chardon L; Chopin-laly X; Raverot V; Caffin AG; Chayvialle JA; Scoazec JY; Lombard-Bohas C Eur J Cancer; 2012 Aug; 48(12):1766-73. PubMed ID: 22133573 [TBL] [Abstract][Full Text] [Related]
6. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414 [TBL] [Abstract][Full Text] [Related]
7. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Nehar D; Lombard-Bohas C; Olivieri S; Claustrat B; Chayvialle JA; Penes MC; Sassolas G; Borson-Chazot F Clin Endocrinol (Oxf); 2004 May; 60(5):644-52. PubMed ID: 15104570 [TBL] [Abstract][Full Text] [Related]
8. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270 [TBL] [Abstract][Full Text] [Related]
9. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Massironi S; Conte D; Sciola V; Spampatti MP; Ciafardini C; Valenti L; Rossi RE; Peracchi M Am J Gastroenterol; 2010 Sep; 105(9):2072-8. PubMed ID: 20372113 [TBL] [Abstract][Full Text] [Related]
10. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Singh S; Law C Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):313-34. PubMed ID: 22646254 [TBL] [Abstract][Full Text] [Related]
11. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors. Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995 [TBL] [Abstract][Full Text] [Related]
13. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Arnold R; Wilke A; Rinke A; Mayer C; Kann PH; Klose KJ; Scherag A; Hahmann M; Müller HH; Barth P Clin Gastroenterol Hepatol; 2008 Jul; 6(7):820-7. PubMed ID: 18547872 [TBL] [Abstract][Full Text] [Related]
14. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors. Modlin IM; Gustafsson BI; Drozdov I; Nadler B; Pfragner R; Kidd M Ann Surg Oncol; 2009 Feb; 16(2):487-98. PubMed ID: 19050963 [TBL] [Abstract][Full Text] [Related]
15. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Abou-Saif A; Gibril F; Ojeaburu JV; Bashir S; Entsuah LK; Asgharian B; Jensen RT Cancer; 2003 Jul; 98(2):249-61. PubMed ID: 12872342 [TBL] [Abstract][Full Text] [Related]
16. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours. Bernini GP; Moretti A; Ferdeghini M; Ricci S; Letizia C; D'Erasmo E; Argenio GF; Salvetti A Br J Cancer; 2001 Mar; 84(5):636-42. PubMed ID: 11237384 [TBL] [Abstract][Full Text] [Related]
17. [Chromogranin A and neuroendocrine tumors]. Díaz Pérez JÁ; Currás Freixes M Endocrinol Nutr; 2013; 60(7):386-95. PubMed ID: 23271036 [TBL] [Abstract][Full Text] [Related]
18. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. Korse CM; Taal BG; de Groot CA; Bakker RH; Bonfrer JM J Clin Oncol; 2009 Sep; 27(26):4293-9. PubMed ID: 19667278 [TBL] [Abstract][Full Text] [Related]
19. Measurements of chromogranin B can serve as a complement to chromogranin A. Stridsberg M; Eriksson B; Fellström B; Kristiansson G; Tiensuu Janson E Regul Pept; 2007 Mar; 139(1-3):80-3. PubMed ID: 17116339 [TBL] [Abstract][Full Text] [Related]
20. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]